TRGNF
Price:
$1.59
Market Cap:
$91.71M
Transgene SA, a biotechnology company, focuses on designing and developing therapeutic vaccines and oncolytic viruses for the treatment of cancer and infectious diseases. It is involved in developing TG4050, a therapeutic vaccine that is in phase I clinical trial for the treatment of ovarian cancer, and human papilloma virus (HPV)-negative head and neck cancers; TG4001, a therapeutic vaccine, which is in phase II clinical trial for the treatment of HPV-positive cancers; TG6002, an oncolytic virus that is in phase I/IIa clinical trial for the treatment of various solid tumors, such as gastrointestinal adenocarcinoma comprising stomach, pancreas, and colon; and BT-001, an oncolytic virus, whic...[Read more]
Industry
Biotechnology
IPO Date
2021-01-08
Stock Exchange
PNK
Ticker
TRGNF
According to Transgene SA’s latest financial reports and current stock price. The company's current PE Ratio is -6.63. This represents a change of -4.33% compared to the average of -6.93 of the last 4 quarters.
The mean historical PE Ratio of Transgene SA over the last ten years is -3.46. The current -6.63 PE Ratio has changed 19.04% with respect to the historical average. Over the past ten years (40 quarters), TRGNF's PE Ratio was at its highest in in the September 2018 quarter at 3.90. The PE Ratio was at its lowest in in the September 2019 quarter at -28.32.
Average
-3.46
Median
-5.68
Minimum
-11.57
Maximum
20.48
Discovering the peaks and valleys of Transgene SA PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 180.87%
Maximum Annual PE Ratio = 20.48
Minimum Annual Increase = -471.61%
Minimum Annual PE Ratio = -11.57
Year | PE Ratio | Change |
---|---|---|
2023 | -6.17 | 22.75% |
2022 | -5.03 | -56.54% |
2021 | -11.57 | 54.84% |
2020 | -7.47 | 23.90% |
2019 | -6.03 | -129.44% |
2018 | 20.48 | -471.61% |
2017 | -5.51 | -5.78% |
2016 | -5.85 | 180.87% |
2015 | -2.08 | -61.54% |
2014 | -5.42 | -14.94% |
The current PE Ratio of Transgene SA (TRGNF) is greater than its 3-year, greater than its 5-year, and less than than its 10-year historical averages
3-year avg
-7.59
5-year avg
-7.25
10-year avg
-3.46
Transgene SA’s PE Ratio is
Company | PE Ratio | Market cap |
---|
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Transgene SA using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Transgene SA or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Transgene SA's PE Ratio?
How is the PE Ratio calculated for Transgene SA (TRGNF)?
What is the highest PE Ratio for Transgene SA (TRGNF)?
What is the 3-year average PE Ratio for Transgene SA (TRGNF)?
What is the 5-year average PE Ratio for Transgene SA (TRGNF)?
How does the current PE Ratio for Transgene SA (TRGNF) compare to its historical average?